<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/82C63573-0D58-431C-840B-51A711518C7D"><gtr:id>82C63573-0D58-431C-840B-51A711518C7D</gtr:id><gtr:firstName>Anna Louise</gtr:firstName><gtr:surname>Goodman</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600424"><gtr:id>16EF4BCB-A06F-44CF-91FF-DA28A494CCDA</gtr:id><gtr:title>The development of a blood-stage vectored vaccine against Plasmodium falciparum malaria</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0600424</gtr:grantReference><gtr:abstractText>Malaria kills over a million children annually and no vaccine is available. Development of a malaria vaccine is difficult, partly because of the parasite?s complex life-cycle stages. I shall investigate producing a vaccine to the blood stage of the life-cycle, that which causes disease, by using a new approach. Developing blood-stage vaccines has been very difficult, and the antibodies induced by various candidate vaccines have so far coferred little protection. However, it has now been found that inducing the other arm of the immune system, cellular immunity and T lymphocytes, may help. This is a less developed field but the Oxford group has made progress in making such a vaccine against the liver-stage of the malaria parasite?s life-cycle. I shall adopt a leading strategy for inducing strong cellular immunity, using safe viral carriers, and try to induce anti-blood stage immunity to the human malaria parasite in a mouse model. Using a genetically engineered mouse parasite I will be able to test the vaccine?s efficacy in mice, then define the immunological characteristics of this protection, and finally explore some potential improvements to this approach. Successful completion of this work should lead to trials in humans of this novel vaccination strategy</gtr:abstractText><gtr:technicalSummary>An effective vaccine against Plasmodium falciparum is urgently needed in order to reduce the global health burden of malaria. Vaccines based on viral vectors have been shown to enhance T cell immunity and increase the diversity of the immune response to intracellular antigens. Their efficacy is increased when more than one type of virus is used in a ?prime-boost? regime. The overall aim and objective of my proposal is to develop viral vector vaccines against malaria using a blood-stage malaria antigen. The ultimate aim would then be to combine the promising liver-stage vaccines produced in our laboratory with an effective blood-stage vaccine. Although most attempts to generate bloodstage malaria vaccines have focused on inducing protective antibodies, recently there has been increasing evidence that cellular immunity to blood-stage antigens play a direct protective role. 
 The malaria antigen I have chosen to work with is the leading blood-stage vaccine antigen, merozoite surface protein 1 (MSP-1) and a combination of its subunits created in our laboratory, known as PfM115. Very recently this antigen has been shown to induce very strong protection against a murine malaria parasite using an adenoviral and poxviral (MVA) vectors in a prime-boost regime that induces both strong antibodies and T cell responses, I aim to test this approach in mice with similar candidate vaccines that encode the MSP-1 antigen from the human parasite P. falciparum. I shall eb able to assess efficacy of these vaccines in mice by employing a novel challenge model. This uses a transgenic parasite, which is a rodent malaria parasite which has had part of the P. falciparum MSP-1 gene inserted in it, avoiding the problem that human malaria parasite do not grow in mice.. This novel method of vaccine testing should minimise the requirement for testing such vaccines in non-human primates.
 I shall initially assess the efficacy of vectored prime-boost vaccines encoding PfM115 employing this chnge model. I shall then seek correlates of the protection observed by undertaking detailed humoral and cellular immunological assays, including detailed mapping of protective epitopes. Finally, I shall explore two potential improvements to this strategy: the use of novel simian adenoviral vectors that should avoid any problems with pre-existing immunity in humans to the adenoviral vectors, and a new genetic adjuvant that may enhance antibody immunogenicity. 
 Successful completion of this project would provide a strong case for assessing this novel approach to a blood-stage malaria vaccine in clinical trials.</gtr:technicalSummary><gtr:fund><gtr:end>2009-10-04</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-09-05</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>159968</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>US National Institutes of Health</gtr:description><gtr:id>0634B301-63EE-4C5D-B903-FBA58C07ECC2</gtr:id><gtr:impact>18660818</gtr:impact><gtr:outcomeId>CA79FFB5C2C-1</gtr:outcomeId><gtr:partnerContribution>Aided in data analysis for publication</gtr:partnerContribution><gtr:piContribution>We provided the samples which were analysed in their laboratory</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Parasitology</gtr:department><gtr:description>Imperial college</gtr:description><gtr:id>9423D0F8-8E60-400A-977D-1A3A37AB0F1F</gtr:id><gtr:impact>Paper in progress</gtr:impact><gtr:outcomeId>hPifaT9QZha-1</gtr:outcomeId><gtr:partnerContribution>Access to mosqitoes and techniques</gtr:partnerContribution><gtr:piContribution>Work directly together on transmission blocking vaccines</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visit (London)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8E269F77-2697-4D31-B50A-EF1FC7D2E939</gtr:id><gtr:impact>Talk led to interest and questions

After my talk school fed back that improved understanding of science and requested I reattend to talk to further classes- so further talk given</gtr:impact><gtr:outcomeId>545a871b9e4749.01082000</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RCPath open day</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>78F337EF-99B2-4424-B7E4-BFAC8C357D64</gtr:id><gtr:impact>This week I will be a facilitator for a group of school pupils- I do not yet know how many will attend

To be seen</gtr:impact><gtr:outcomeId>ob7vNbmqyAZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open day- at our laboratory</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E9A10F90-683C-4CD9-816C-0B630FAF0F42</gtr:id><gtr:impact>Open day to aid understanding of science

Media interest</gtr:impact><gtr:outcomeId>AE6C1468A0C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BIA research fellowship</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>British Infection Association (BIA)</gtr:fundingOrg><gtr:id>0B5C05EC-ECF9-4FA5-91D7-8047856D12C7</gtr:id><gtr:outcomeId>QvBpUMKJ1Vo</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Continuing development of viral vector technology, with reference to malaria vaccines but applicable to other viral vector vaccines.</gtr:description><gtr:grantRef>G0600424</gtr:grantRef><gtr:id>7F6EF06A-1115-4CB6-8843-52B3B3662FBE</gtr:id><gtr:impact>Further vaccine development</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>WwjxD2RHo5t</gtr:outcomeId><gtr:patentId>WO2008122811</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>novel adenovirus patent applications covering malaria vectored vaccines and immunization regimes</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Blood-stage malaria vaccine, recently commenced phase I trials in humans.</gtr:description><gtr:id>6C92FB94-6D07-4F51-9E9D-1605DB84AEAF</gtr:id><gtr:impact>Results not yet assessed, expected early 2010.</gtr:impact><gtr:outcomeId>8E4B96285C3</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>AdHu5 PfMSP-1</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0C5220D2-C37A-4EAB-9755-671D623396D9</gtr:id><gtr:title>Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42a04bc2b2520d2067cacef47b23c82b"><gtr:id>42a04bc2b2520d2067cacef47b23c82b</gtr:id><gtr:otherNames>de Cassan SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5675e9700b93e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE8CA5A8-6595-48F4-8BC2-51F87B7693D3</gtr:id><gtr:title>Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2787dfca57d8c2fdc2e07cd71617963"><gtr:id>a2787dfca57d8c2fdc2e07cd71617963</gtr:id><gtr:otherNames>Ewer KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_540e14ae14aa4e316</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25FD5BFC-8E9F-4B46-86B9-2C5C28D2DBB3</gtr:id><gtr:title>Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2da65024ea62296e117b26b34c3dc53a"><gtr:id>2da65024ea62296e117b26b34c3dc53a</gtr:id><gtr:otherNames>O'Hara GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_13593_23_22275401</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>343DC2FE-AFBF-43E0-BB37-2EDFA2C18100</gtr:id><gtr:title>T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc38a3c8d7daa55241aa596afb1e2901"><gtr:id>cc38a3c8d7daa55241aa596afb1e2901</gtr:id><gtr:otherNames>Forbes EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13593_23_22984589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07972C84-44D6-4963-81CA-2F04F8BCC984</gtr:id><gtr:title>Effective induction of high-titer antibodies by viral vector vaccines.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40d40b441e7b9e50b5b7a28e5fe12d96"><gtr:id>40d40b441e7b9e50b5b7a28e5fe12d96</gtr:id><gtr:otherNames>Draper SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>F9FE929D22E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F08D520C-5C8A-48B3-A743-B1228002CF44</gtr:id><gtr:title>A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2546e47efb1bfb085a82655340383cb4"><gtr:id>2546e47efb1bfb085a82655340383cb4</gtr:id><gtr:otherNames>Goodman AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13593_23_22216279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2653511E-CCB6-4D60-80CC-1E812192D4A6</gtr:id><gtr:title>The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2546e47efb1bfb085a82655340383cb4"><gtr:id>2546e47efb1bfb085a82655340383cb4</gtr:id><gtr:otherNames>Goodman AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>pm_13593_23_23609325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36AAF462-2A87-4C6E-8E1E-EC4AC9E0B3F3</gtr:id><gtr:title>The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c14f468562fffaa13dd59e4fc7fddc23"><gtr:id>c14f468562fffaa13dd59e4fc7fddc23</gtr:id><gtr:otherNames>Douglas AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_13593_23_22186897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F27F70A4-C824-4F54-AAD1-4B3454030125</gtr:id><gtr:title>New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2546e47efb1bfb085a82655340383cb4"><gtr:id>2546e47efb1bfb085a82655340383cb4</gtr:id><gtr:otherNames>Goodman AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>rb7bH9NvYy1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7296CA7-174D-4B38-932B-17F2A4A715E8</gtr:id><gtr:title>Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4f8fba304c35dd62dbda644b9b48af2"><gtr:id>b4f8fba304c35dd62dbda644b9b48af2</gtr:id><gtr:otherNames>Kapulu MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5675e64134fc8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>576A02D9-7E72-4977-A97E-5D20188DC32F</gtr:id><gtr:title>Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89949182e9b3ddd5223b9cd10caaeba4"><gtr:id>89949182e9b3ddd5223b9cd10caaeba4</gtr:id><gtr:otherNames>Larsen KC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5EE6692CAC3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D61F182-3F2C-4975-92FC-534F126104A7</gtr:id><gtr:title>Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40d40b441e7b9e50b5b7a28e5fe12d96"><gtr:id>40d40b441e7b9e50b5b7a28e5fe12d96</gtr:id><gtr:otherNames>Draper SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn><gtr:outcomeId>C472A0314D7</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600424</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>